The goal of this study was to evaluate in vitro and in vivo the effects of up-regulation of the proangiogenic hypoxia inducible factor (HIF)-1␣ induced by dimethyloxalylglycine on endothelial cell cultures and on skin flap survival. Methods: Human umbilical vein endothelial cell cultures were exposed to hypoxic conditions, to dimethyloxalylglycine, and to cobalt chloride for up to 24 hours. Expression of HIF-1␣ and vascular endothelial growth factor (VEGF) in cell culture media was analyzed. In vivo, 20 male Wistar rats were assigned randomly to either the treatment group (dimethyloxalylglycine intraperitoneal injection, n ϭ 10) or the control group (saline intraperitoneal injection, n ϭ 10). A dorsal skin flap was raised in all animals and sutured back into place. Flap survival was evaluated on postoperative day 7 by laser Doppler and digital planimetry. Reconstr. Surg. 128: 415, 2011.) 
D
efect coverage using local skin flaps is still a pillar in plastic reconstructive surgery. For this purpose, random-pattern skin flaps provide a reproducible and relatively safe method for reconstruction. However, in all random skin flaps, distal flap necrosis resulting in failed reconstruction remains a serious complication. This applies particularly for the distal part of the flap that covers the initial defect.
Many approaches have been designed to reduce distal flap necrosis. Among them, flap delay 1 is probably the most effective but requires at least one additional surgical intervention with its inherent drawbacks. Another approach is the perioperative use of pharmacologic agents to enhance flap perfusion and survival. Studies have investigated the effect of systemic, 2,3 local, 4 ,5 and combined 6 pharmaceutical applications on flap survival. It has been shown that an important factor of randompattern flap survival is the effect of angiogenesis. 7 Angiogenic factors such as vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-␤ delivered by adenovirus-mediated gene therapy have been reported to be effective in reducing skin flap necrosis. 8, 9 However, the application of adenoviruses as vectors in clinical use is limited because of infectious concerns that have prevented clinical application for this purpose so far.
Recent studies investigated the role of hypoxia-inducible factor (HIF) in cellular response to ischemia. 10, 11 HIF is a heterodimer consisting of a constitutively expressed HIF-1␤ subunit and an oxygen tension-controlled HIF-1␣ subunit. HIF-1␣ induces in the cell nucleus the transcription of different angiogenic factors such as VEGF, TGF-␤, and angiopoietin. The activity of HIF-1␣ is modulated by a group of enzymes called HIF prolyl hydroxylases responsible for degrading HIF-1␣ under normoxic conditions. 12 Inhibition of these enzymes by dimethyloxalylglycine has resulted in a significant increase of HIF-1␣ concentrations in ischemic rat myocardium and reduction of infarct size 13 and a significant increase of angiogenesis in ischemic mouse skeletal muscle. 14 Other studies suggest that dimethyloxalylglycine acts to stabilize HIF-1␣ expression at normal oxygen tension levels in cultured cells and is believed to act as a proangiogenic compound by means of the HIF-1␣ system. 15 These previous experimental results show an important angiogenic potential of HIF-1␣ stabilization by means of dimethyloxalylglycine administration, leading us to the hypothesis that dimethyloxalylglycine might be beneficial in reducing necrosis in ischemic skin flaps. This study was designed to investigate the effects of dimethyloxalylglycine on HIF-1␣ on cultured endothelial cells both in vitro and in vivo, and in a standardized experimental random pattern flap model in rats.
MATERIALS AND METHODS

Chemicals and Reagents
HIF-1␣ antibody was purchased from Novus Biologicals (Littleton, Col.), horseradish peroxidase anti-rabbit secondary antibody was purchased from Abcam (Cambridge, United Kingdom), and all media for cell culture were purchased from Promo Cell (Heidelberg, Germany). Human umbilical vein endothelial cells were a generous gift of the Department of Clinical Research of the University of Bern. Dimethyloxalylglycine was purchased from Cayman Chemical (Ann Arbor, Mich.).
Cell Culture
Human umbilical vein endothelial cells were isolated from the vein of the umbilical cord and were grown as a monolayer in Endothelial Cell Growth Medium MV (Promo Cell) supplemented with 2% volume/volume fetal calf serum, 0.004 ml/ml endothelial cell growth supplement, 10 ng/ml epidermal growth factor (recombinant human), 90 g/ml heparin, 1 g/ml hydrocortisone, and 1% penicillin-streptomycin. The cells were cultured in T-25 (25 cm 2 ) culture flasks and maintained at 37°C in a 5% carbon dioxide humidified atmosphere. Cells were passaged on reaching 90 to 95 percent confluence.
Experimental Protocol
All experiments were performed at a cell confluence of 90 to 95 percent. For the studies concerning the effect of HIF-1␣ activator, cells were incubated with the hypoxia-mimetic compound dimethyloxalylglycine (1 mM, dissolved in ethanol) for 2, 4, 6, and 24 hours at normoxic conditions. At the end of incubation times, cells were lysed and used for Western blot analysis of HIF-1␣, and cellular supernatants were measured for VEGF content using enzyme-linked immunosorbent assay. Cobalt chloride (600 M for 4 and 6 hours) mimics hypoxia and was used as a positive control for HIF-1␣ activation. As an additional control, we investigated the effect of hypoxic conditions (i.e., hypoxia chamber, 1.5% oxygen, 37°C, carbon dioxide, and humidity for 24 hours) on VEGF and HIF-1␣ expression levels.
Western Blot Analysis
Cells were lysed in 60 mM tris(hydroxymethyl)aminomethane, 8.5% glycerol, and 2% sodium dodecyl sulfate. The protein concentration was determined with the Quant-iT assay kit (Invitrogen, Basel, Switzerland) and read with the Qubit Fluorometer (Invitrogen). Equal amounts of protein (20 mg per line) were loaded and separated by 4 to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Gels were then transferred into nitrocellulose membranes with the iBlot dry blotting system (Invitrogen). Equal loading was verified by staining the ex-gel with SimplyBlue SafeStain (Invitrogen). Afterward, the membranes were blocked for 30 minutes with the incubation buffer [10 mM tris(hydroxymethyl)aminomethane, pH 7.5, 100 mM sodium chloride, and 0.1% weight/volume Tween 20] supplemented with 5% nonfat dry skim milk, and then incubated overnight with the primary antibodies: HIF-1␣ polyclonal antibody (dilution, 1:2000) and antiactin antibody (dilution, 1:3000). The membranes were then washed three times with incubation buffer Plastic and Reconstructive Surgery • August 2011 and incubated for 1 hour with horseradish peroxidase goat polyclonal anti-rabbit immunoglobulin G (dilution, 1:3000). Afterward, membranes were developed with the enhanced chemiluminescence detection kit (Pierce, Rockford, Ill.). All Western blotting experiments were performed in triplicate.
Enzyme-Linked Immunosorbent Assay
Enzyme-linked immunosorbent assay for VEGF content in cell supernatants was performed according to the manufacturer's instructions (Invitrogen) in duplicate.
Animal Model
After approval of the responsible committee for animal care (approval 117/09, Tierschutzkommission des Kantons Bern), 20 male Wistar rats (weight, 300 to 350 g) were assigned randomly to either the control group (n ϭ 10) or the treatment group (n ϭ 10). All animals were treated according to the Public Health Service Policy on Humane Care and Use of Laboratory Animals (National Institutes of Health, updated 1996) throughout the entire experiment. All animals were provided with standard laboratory food and water ad libitum before and after the procedures.
Surgical Procedure
The surgical procedure was performed under general anesthesia by intraperitoneal injection of a mixture of 0.05 mg of fentanyl, 20 mg of midazolam, and 1.5 mg of medetomidine dissolved in 10 ml of sodium chloride 0.9% at a dose of 3 ml/kg body weight. Adequate anesthesia depth was ascertained by the pinch flexion/withdrawal test, and the skin of the dorsum was shaved with electric clippers. A caudally pedicled flap measuring 3 ϫ 9 cm was marked on the dorsum of the animals symmetric to the spine, in keeping with the commonly used modification of the McFarlane flap. 16, 17 Under aseptic conditions, the flap was raised in a plane deep to the panniculus carnosus. After careful hemostasis, the flap was resutured into the defect using 4-0 monofilament resorbable sutures. Postoperative analgesia was ensured in all animals by oral administration of metamizole (Novalgin; Sanofi-Aventis, Geneva, Switzerland). 50 mg/kg mixed in the drinking water. Group II (treatment group) received intraperitoneal administration of dimethyloxalylglycine (Cayman Chemicals) at a dosage of 40 mg/kg body weight 3 days before the surgical procedure (day -3), at the time of surgery (day 0), and 2 days after surgery (day 2). Group I (control group) received intraperitoneal injections of sterile saline solution at the same time points as the treatment group.
Flap Survival Evaluation
The evaluation of flap viability was performed on postoperative day 7, when a clearly demarcated zone of distal necrosis was seen in both groups. For evaluation, the animals were reanesthetized using the same protocol as described above.
The necrotic flap area was assessed by standardized digital photographs of the dorsum of each rat. Using image-editing software (NISElements AR; Nikon Instruments, Inc., Melville, N.Y.), the area of necrosis relative to the total area of the flap was computed by dividing the number of pixels constituting the necrotic areal to the number of pixels constituting the whole flap.
The laser Doppler imaging of the dorsal random-pattern flap was undertaken on the seventh postoperative day, before the animals were killed, using the MoorLDI2-IR Laser Doppler Imager (Moor Instruments Ltd., Axminster, Devon, United Kingdom). The readings were subsequently analyzed using MOORLDI Software Research Version 5.3 (Moor Instruments) by recording the mean blood flow at seven equally distanced points from the base to the tip of the flap. The readings were than expressed as percentage of blood flow increase or decrease related to the measurement at the base of the flap (Fig. 1) . After the laser Doppler assessment, the anesthetized animals were killed by intracardiac injection of a lethal dose of potassium chloride.
Statistical Analysis
All results are expressed as means Ϯ SD. The results were analyzed by analysis of variance using SPSS software (SPSS, Inc., Chicago, Ill.), and statistical significance was assumed at p Ͻ 0.05 unless otherwise specified.
RESULTS
In Vitro Study Elevation of HIF-1␣ Protein Level by Dimethyloxalylglycine
Human umbilical vein endothelial cells were treated with dimethyloxalylglycine (1 mM) at normoxic conditions, and HIF-1␣ protein level was assessed by Western blot analysis of cell extract. Dimethyloxalylglycine induced the expression of HIF-1␣ in a time-dependent manner relative to (Fig. 2) . Cobalt chloride (a chemical inducer of HIF-1␣) was used as a positive control (600 mM), and also induced reproducibly strong expression of HIF-1␣ after 4 and 6 hours of incubation.
VEGF Expression by Dimethyloxalylglycine and under Hypoxic Conditions
Because HIF-1␣ is considered the main transacting factor in controlling the rate of transcription of the VEGF gene, 18 VEGF was measured in cell culture medium to determine whether HIF-1␣ enhancement by dimethyloxalylglycine would also modify VEGF release from cells. Human umbilical vein endothelial cells were treated with dimethyloxalylglycine (1 mM) under normoxic conditions, and after 24 hours, VEGF content in culture medium was determined by enzyme-linked immunosorbent assay. Treatment with dimethyloxalylglycine significantly induced production of VEGF compared with untreated control cells (92 Ϯ 35 pg/mg versus 23 Ϯ 10 pg/mg total cellular protein; p Ͻ 0.05) (Fig. 3) . As HIF-1␣ is stabilized Fig. 1 . Design of the laser Doppler blood flow assessment test with flap base reference point and distal reading points. Fig. 2 . HIF-1␣ expression after normoxic incubation with dimethyloxalylglycine (DMOG) (at 1 mM for 2, 4, 6, and 24 hours) and cobalt chloride (CoCl 2 ) (at 600 M for 4 and 6 hours; n ϭ 3) (*p Ͻ 0.05 versus control). Actin was used as a protein loading control. 
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under hypoxic conditions and given that HIF-1␣ is the main regulator of VEGF expression in hypoxia, 19 the capacity of human umbilical vein endothelial cells to up-regulate VEGF production in response to hypoxia (1.5% oxygen) was also evaluated as a positive control. Hypoxia-induced secretion of VEGF by human umbilical vein endothelial cells was increased by incubation for 24 hours under hypoxic conditions (88 Ϯ 21 pg/mg versus 23 Ϯ 10 pg/mg total cellular protein; p Ͻ 0.05).
In Vivo Experiment
All animals survived throughout the 7 follow-up days and were evaluated for flap survival, and by means of laser Doppler examination.
Flap Survival
Necrosis occurred constantly in the distal region of the flap in all animals. The digital photographs taken on postoperative day 7 showed the characteristic distribution of necrosis and the visible differences between the two groups (Fig. 4) . Software analysis showed a higher necrosis rate of 44.42 Ϯ 5.18 percent in the control group compared with the dimethyloxalylglycine-treated group, with 35.95 Ϯ 5.03 percent (p Ͻ 0.05) (Table 1).
The laser Doppler investigation of the dorsal skin flaps of the rats performed on postoperative day 7 showed a characteristic difference in the readings at points 2 to 5 located at 1.5, 3, 4.5, and 6 cm distal to the flap base between the two groups (Fig. 5 ). There was a significantly higher mean blood flow in the proximal two-thirds of the flap in the treatment group compared with the control group (p Ͻ 0.05).
DISCUSSION
This study indicates that inhibition of HIFdegrading enzyme by dimethyloxalylglycine can increase HIF-1␣ concentrations in endothelial cells and improve skin flap survival in the rat model. Flap reconstruction of tissue is a procedure Flap necrosis usually occurs at its distal end and thus the defect area remains partially uncovered. This leads to unavoidable delays in healing and subsequent additional operations. The current research focuses on pharmacologic support of skin perfusion to improve survival in random pattern flaps. This therapeutic approach is in line with a series of recent experimental studies. 20 -23 Improvement of perfusion and/or angiogenesis with implications in pathologic states contributes significantly to success or failure of reconstructive procedures, especially in flap surgery. Successful augmentation of flap vascularity has been described with the use of VEGF, 8 TGF-␤, 9 fibroblast growth factor-2, 24,25 and angiopoietin-1 and angiopoietin-2. 26, 27 Other studies concluded that a combination of these cytokines is more potent in angiogenesis than each single factor alone. 28, 29 Studies have shown the angiogenic benefits of combining VEGF and other cytokines in adult neovascularization. 30 -32 However, constant delivery of these multiple factors with short bioactive half-lives still depends on the clinically cumbersome methods of adenovirus-mediated transfection. 8, 9 Alternative approaches might include increasing the levels of key factors that influence a number of other potent cytokines or extending the half-life of growth factors by pharmacologic inhibition of their degrading enzymes.
Increasing HIF concentration appears to be well suited for this approach. In recent years, studies have focused on the mechanisms involving the HIF protein family as the main regulator of cellular response to low oxygen levels in mammals, playing a key role in angiogenesis. 10 HIF-1 is the prototype of this family of heterodimers, consisting of a constitutively expressed HIF-1␤ subunit and an oxygen-regulated HIF-1␣ subunit. In vivo studies have shown that adenovirus-associated gene transfer of a constitutively active form of HIF-1␣ significantly increased blood flow in a rabbit model of lower limb ischemia 33 and increased perfusion of murine skeletal muscle. 34 In a mouse ischemia model, aging impaired endothelial progenitor cell trafficking to sites of ischemia through a failure of aged tissues to normally activate the HIF-1␣ during ischemia. Intraperitoneal administration of the iron chelator desferrioxamine (a pharmacologic HIF-1 inducer) to aged mice restored HIF-1␣ expression in an ischemic skin flap, increased ischemia-induced mobilization of endothelial progenitor cells, and improved flap vascularization, leading to tissue survival that was comparable to that of young mice. 
Plastic and Reconstructive Surgery • August 2011
The mechanism of HIF activation and deactivation is dependent on a family of proteins called the HIF prolyl hydroxylases. Under normoxemic conditions, HIF-1␣ and HIF-2␣ (which are continuously synthesized) become hydroxylated at one of the proline residues Pro402 or Pro564 under the effect of HIF prolyl hydroxylases. This process of hydroxylation ceases under hypoxemic conditions, leading to stabilization of HIF-1␣. 36 Substances that inhibit HIF prolyl hydroxylases would lead to subsequent HIF-1␣ stabilization. A whole range of substances called prolyl-4-hydroxylase inhibitors were detected and synthesized, including specific inhibitors such as PHI-1, FG-4497, TM 6008, and TM 6089 37 and nonspecific inhibitors such as desferrioxamine and dimethyloxalylglycine. 38 Dimethyloxalylglycine has a nonspecific effect of inhibition of HIF prolyl hydroxylases, resulting in stabilization of HIF-1␣. The HIF stabilization 39 following dimethyloxalylglycine therapy was demonstrated in recent in vivo studies in ischemic rat myocardium, leading to reduction of infarct size 13 and a significant increase of angiogenesis in ischemic rat skeletal muscle.
14 Our in vitro study parallels these findings of HIF-1␣ stabilization, demonstrating its application in endothelial cell cultures, with dimethyloxalylglycine acting as a hypoxia-mimetic drug, stabilizing HIF-1␣ and consecutively producing VEGF.
The presented in vivo results demonstrated significantly augmented flap survival compared with untreated controls following three intraperitoneal injections of dimethyloxalylglycine (40 mg/kg). The model used offers reliable flap ischemia and was already proven to be a reliable and well-established rat flap design. 16, 17 By adding dimethyloxalylglycine and inhibiting the degrading prolyl-4-hydroxylase inhibitor action, in the flap environment, HIF-1␣ can benefit from a longer activity period, thus allowing overexpression of cytokines such as VEGF, TGF-␤, and angiopoietin, which have been shown to reduce flap necrosis. The suggested cellular pathway-dimethyloxalylglycine to HIF-1␣ stabilization to angiogenic cytokine overexpression-might be responsible for the significant improvement in flap survival observed in the current study.
The laser Doppler observations demonstrate a significant difference in flap blood flow pattern between the two groups. In the treatment group, blood flow is maintained at relatively constant high levels in the proximal two-thirds of the flap before decreasing to low levels in the distal necrotic parts of the flap, whereas the untreated controls display a constant decrease of perfusion throughout the flap. This flap blood flow pattern would suggest increased vascularization in the proximal flap, probably by HIF-1␣-enhanced overexpression of VEGF, whose angiogenic effects are well documented. This early proximally enhanced blood flow is very likely to lead to better flap survival in the treatment group.
CONCLUSIONS
The nonselective inhibition of the HIF-1␣ degradation pathway with a prolyl-4 hydroxylase inhibitor, dimethyloxalylglycine, showed statistically significant positive effects both in endothelial cell cultures and in rodent skin flap survival. Further studies are necessary to delineate the precise mechanism by which dimethyloxalylglycine leads to the observed positive effects in vivo and to determine possible clinical applications of these experimental results. An in vivo assessment of the levels of dimethyloxalylglycine, HIF, and different angiogenesis factors in the flap tissue will further elucidate increased flap survival by HIF-induced mechanisms. The presented results on inhibition of HIF degradation and increased flap survival point toward a new line of research for angiogenesis in skin flap survival.
